Prothena Corp. (NASDAQ:PRTA) shot up 1.7% on Thursday . The stock traded as high as $41.48 and last traded at $41.25, with a volume of 218,554 shares traded. The stock had previously closed at $40.55.

Several brokerages have recently weighed in on PRTA. Zacks Investment Research raised shares of Prothena Corp. from a “sell” rating to a “hold” rating in a research report on Friday, May 6th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Prothena Corp. in a research report on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Prothena Corp. in a research report on Tuesday. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Prothena Corp. in a research report on Tuesday, March 15th. Finally, Barclays PLC initiated coverage on shares of Prothena Corp. in a research report on Friday, May 13th. They set an “overweight” rating and a $60.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Prothena Corp. has an average rating of “Buy” and an average price target of $74.60.

The stock has a 50-day moving average price of $43.24 and a 200-day moving average price of $42.83. The company’s market capitalization is $1.51 billion.

Prothena Corp. (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.04. Equities analysts expect that Prothena Corp. will post ($3.72) EPS for the current year.

In related news, Director Dennis J. Selkoe sold 5,000 shares of Prothena Corp. stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $45.00, for a total value of $225,000.00. Following the completion of the transaction, the director now owns 3,025 shares in the company, valued at $136,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Karin L. Walker sold 4,000 shares of Prothena Corp. stock in a transaction that occurred on Wednesday, April 13th. The shares were sold at an average price of $45.11, for a total transaction of $180,440.00. Following the completion of the transaction, the insider now owns 2,000 shares of the company’s stock, valued at approximately $90,220. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have made changes to their positions in the company. Columbus Circle Investors boosted its position in shares of Prothena Corp. by 36.9% in the fourth quarter. Columbus Circle Investors now owns 218,943 shares of the company’s stock worth $14,912,000 after buying an additional 58,987 shares during the period. California State Teachers Retirement System boosted its position in shares of Prothena Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 57,940 shares of the company’s stock worth $3,946,000 after buying an additional 900 shares during the period. American Century Companies Inc. boosted its position in shares of Prothena Corp. by 36.8% in the fourth quarter. American Century Companies Inc. now owns 41,054 shares of the company’s stock worth $2,796,000 after buying an additional 11,043 shares during the period. Nationwide Fund Advisors boosted its position in shares of Prothena Corp. by 77.8% in the fourth quarter. Nationwide Fund Advisors now owns 35,835 shares of the company’s stock worth $2,441,000 after buying an additional 15,683 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock worth $1,182,000 after buying an additional 803 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.